DEF: Emergent BioSolutions Details 2026 Annual Meeting Agenda

Emergent BioSolutions announces its 2026 annual meeting of stockholders, detailing director elections, auditor ratification, executive compensation, and a critical proposal to increase shares for its stock incentive plan.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on Wednesday, April 29, 2026, at 9:00 a.m., Eastern Time.
• Key proposals include the election of four Class II directors (Sujata Dayal, John Fowler, Jr., Zsolt Harsanyi, Ph.D., and Joseph Papa), the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026, an advisory vote to approve 2025 named executive officer (NEO) compensation, and the approval of an amendment to the Stock Incentive Plan to increase the number of shares available for awards.
• Emergent BioSolutions reported a net income of $52.6 million for 2025, a significant improvement from a net loss of $(190.6) million in 2024.
• Adjusted net income for 2025 was $86.8 million, compared to an adjusted net loss of $12.1 million in 2024.
• Adjusted EBITDA increased to $205.0 million in 2025 from $183.1 million in 2024.
• Total revenue for 2025 was $742.9 million, a decrease from $1,043.6 million in 2024.
• The company's net leverage ratio improved to 1.9x adjusted EBITDA as of December 31, 2025, down from 3.3x in 2024.
• The 2025 annual cash incentive awards for executives were paid out at 107% of target, reflecting performance that exceeded expectations.
• Performance Stock Units (PSUs) granted for the 2023-2025 period were paid out at 25%, a discretionary upward adjustment as the adjusted EBITDA margin of 12.9% was slightly below the 13.0% threshold target.
• The proposed amendment to the Stock Incentive Plan seeks to add 5,000,000 shares, which is deemed critical for attracting, retaining, and motivating talent; 2,043,910 contingent awards will be forfeited if the amendment is not approved.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. While the company demonstrated significant financial improvements and strategic progress in its turnaround, the need for a substantial increase in the share pool for equity awards and the discretionary payout of PSUs indicate ongoing challenges in aligning compensation with performance and managing share dilution.

Positives

• The company made significant progress in its turnaround strategy, with 2025 performance exceeding initial expectations.
• Net income improved substantially to $52.6 million in 2025 from a loss of $(190.6) million in 2024.
• Adjusted net income turned positive to $86.8 million in 2025 from a loss of $12.1 million in 2024.
• Adjusted EBITDA increased to $205.0 million in 2025 from $183.1 million in 2024.
• Net leverage ratio improved significantly to 1.9x adjusted EBITDA in 2025 from 3.3x in 2024.
• Repaid $100 million of debt with cash on hand in 2025.
• Sold the Baltimore-Bayview facility for $36.5 million while retaining rights to secure manufacturing capacity.
• Initiated a stock repurchase program, repurchasing $24.8 million of common stock in 2025, and reauthorized an additional $50 million through March 31, 2027.
• Included in the Russell 3000 Index effective June 27, 2025.
• Announced approximately $303 million in medical countermeasures (MCM) contract options.
• Gained exclusive commercial rights to KLOXXADO (naloxone HCI) Nasal Spray 8 mg in the United States and Canada.
• Expanded the proprietary NARCANDirect online distribution network to include KLOXXADO.
• Received U.S. FDA approval for drug product manufacturing of raxibacumab at the Winnipeg, Canada facility.
• Resolved legacy legal disputes and improved quality and compliance outcomes.
• Annual cash incentive awards for 2025 were paid out at 107%, indicating strong corporate performance against targets.

Negatives

• Total revenue decreased to $742.9 million in 2025 from $1,043.6 million in 2024, representing a significant decline.
• The 2023-2025 Performance Stock Units (PSUs) did not meet the threshold performance target (12.9% adjusted EBITDA margin vs. 13.0% threshold), requiring upward discretion by the Compensation Committee for a 25% payout.
• The company faces limited available share pool constraints for equity grants, necessitating stockholder approval for an amendment to the Stock Incentive Plan.
• Contingent equity awards for executives and employees, totaling 2,043,910 shares, will be automatically forfeited if the Plan amendment is not approved, potentially impacting talent retention and motivation.
• If the Plan amendment is not approved, the company would be compelled to rely more heavily on cash-based incentives, which could limit financial flexibility.
• The proposed increase in the share reserve for the Stock Incentive Plan is estimated to result in an overall potential dilution of approximately 9% of common stock outstanding.
• As of March 6, 2026, 24% of the shares underlying outstanding stock option awards are underwater, with a weighted-average exercise price of $16.52 per share compared to the $8.29 closing price on March 6, 2025.

Risks

• Risk of not attracting, retaining, and motivating experienced and capable employees if the proposed increase in the Stock Incentive Plan shares is not approved, leading to forfeiture of contingent awards and reliance on less flexible cash incentives.
• Operational and reputational risks associated with compliance with laws, regulations, and industry standards (GxP, healthcare compliance, anti-corruption, privacy, data security, medical product safety, supply chain, employee health and safety, political expenditures, lobbying activities, and government contracting).
• Cyber and information security risks, which are under the oversight of the Quality, Compliance, Manufacturing and Risk Management Committee.
• Financial risks, including those related to financial planning, capital structures, issuance of securities, and use of derivatives, overseen by the Audit and Finance Committee.
• Legal matters that may have a material impact on the company's financial statements, accounting policies, or compliance.
• Potential adverse tax consequences on compensation treated as excess parachute payments under Sections 280G and 4999 of the Internal Revenue Code.

Future Outlook

The company is advancing its 2026 priorities, focusing on driving growth in core Commercial and Medical Countermeasures (MCM) segments, strategically expanding internationally, reinforcing patient safety, quality, and compliance, and leveraging bipartisan support for preparedness. The Board is confident in the company's ability to transform the business to deliver long-term, sustainable value for stockholders.

Management Comments

• At Emergent, our mission is to protect and save lives.
• Our vision is to become the leader in solving health threats for communities around the world.
• Over the past year, Emergent has taken strategic actions to strengthen the business and make significant progress in its turnaround.
• With a diverse portfolio of medical countermeasures and opioid overdose emergency products, Emergent is well positioned to execute its transformation strategy.
• The Board of Directors is confident in Emergents ability to transform the business to deliver long-term, sustainable value for stockholders, while continuing the important work of protecting communities from health threats.
• We will continue working to provide strong governance and independent oversight to represent your interests as Emergent continues its turnaround and transformation for the future.
• The Compensation Committee believes this outcome appropriately balances payforperformance alignment with the need to retain and motivate senior leadership.
• The Compensation Committee recognizes that the use of discretion in these circumstances is not a routine practice and expects such discretion to remain limited and factspecific.

Industry Context

StockSavvy.ai notes that Emergent BioSolutions operates in the critical and highly regulated biopharmaceutical and public health sectors, specializing in medical countermeasures and opioid overdose emergency products. The company's strategic focus on strengthening its business and executing a turnaround plan aligns with broader industry trends emphasizing resilience, diversified portfolios, and addressing pressing public health challenges. The continued collaboration with government entities for medical countermeasures highlights its unique position in a niche market, while expansion into commercial products like KLOXXADO positions it to address endemic health threats. The challenges in executive compensation, particularly the need for increased share pools, reflect the competitive talent landscape within the biotech and pharma industries.

Comparison to Industry Standards

• The company's Total Shareholder Return (TSR) is compared against the S&P 500 Biotechnology Index, which serves as a relevant benchmark for its industry.
• The compensation peer groups for executive officers are reviewed annually, considering publicly traded pharmaceutical, biotechnology, and healthcare equipment/life sciences tools and services companies with comparable revenues, market capitalization, net income, headcount, and R&D expense.
• The company's executive compensation program targets the 50th percentile of competitive market data, aligning with common industry practice for attracting and retaining talent.
• The use of equity-based compensation (stock options, RSUs, PSUs) is a standard practice in the biopharmaceutical industry to align executive interests with long-term shareholder value, similar to companies like Pfizer, Johnson & Johnson, and Novartis, where some of Emergent's executives previously held roles.

Management Changes

Corporate Governance

Legal Proceedings

• Resolved legacy legal disputes and improved quality and compliance outcomes.

Related Party Transactions

• Since January 1, 2025, there were no related party transactions, nor are there currently any proposed related party transactions, which in accordance with SEC rules, would require disclosure in this proxy statement.

Stakeholder Impact

• Shareholders: Potential dilution from the proposed increase in the stock incentive plan shares (estimated 9% overall potential dilution, 24% fully diluted). However, the plan is intended to drive long-term value through talent retention and motivation. The stock repurchase program aims to return value to shareholders.
• Employees: The proposed increase in the stock incentive plan shares is crucial for attracting, retaining, and motivating employees through competitive equity-based compensation. Forfeiture of contingent awards if the plan is not approved could negatively impact employee morale and retention.
• Customers: Continued focus on delivering protective and life-saving solutions, including medical countermeasures and opioid overdose emergency products, directly benefits customers and communities.
• Management: Executive compensation is tied to performance, with a significant portion being variable and equity-based, aligning their interests with company performance and shareholder value. The revised clawback policy increases accountability.

Next Steps

• Stockholders to elect Class II directors at the 2026 annual meeting on April 29, 2026.
• Stockholders to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
• Stockholders to hold an advisory vote to approve the 2025 compensation of named executive officers.
• Stockholders to approve an amendment to the Stock Incentive Plan to increase the number of shares of common stock for the grant of awards.
• Company to continue executing its transformation strategy, focusing on growth in Commercial and MCM segments, international expansion, quality, compliance, and public health preparedness.
• Marvin White will retire as CEO and assume Executive Chair role of Aptevo Board of Directors effective April 1, 2026.
• Company anticipates making future requests for additional increases in the share reserve periodically.

Key Dates

Recommendation

The company shows promising signs of a turnaround with improved net income and adjusted EBITDA, along with a stronger balance sheet through debt repayment and reduced net leverage. Strategic actions like facility sale and product rights acquisition are positive. However, the significant revenue decline and the need for substantial share dilution to fund future equity compensation, coupled with the discretionary payout of PSUs despite not meeting the threshold, suggest ongoing challenges and a need for sustained execution. The stock repurchase program offers some support, but the overall picture warrants a 'hold' as the turnaround progresses and the impact of dilution and future performance becomes clearer.

Keywords

Emergent BioSolutions, Proxy Statement, Executive Compensation, Stock Incentive Plan, Corporate Governance, Medical Countermeasures, Opioid Epidemic, NARCAN, KLOXXADO, Biotechnology, Pharmaceuticals, Public Health, Financial Performance, Adjusted EBITDA, Net Leverage, Stock Repurchase, Director Election, Auditor Ratification, Shareholder Meeting, SEC Filing